lopinavir

lopinavir
Drug name	Lopinavir
Tradename	Kaletra, Aluvia
Routes of administration	Oral
ATC prefix	J05
ATC suffix	AR10
Legal status	Rx-only

lopinavir

Lopinavir is an antiretroviral medication used in combination regimens for the treatment of human immunodeficiency virus infection. It is most commonly co-formulated with ritonavir and prescribed as part of combination therapy that often involves drugs from the World Health Organization recommendations and national treatment guidelines such as those of the United States Department of Health and Human Services and the European Medicines Agency. Developed in the late 20th century by a team associated with AbbVie and Bristol-Myers Squibb researchers, lopinavir has been included in formularies and procurement lists managed by organizations like Médecins Sans Frontières and the Global Fund.

Medical uses

Lopinavir is indicated for the treatment of Acquired Immune Deficiency Syndrome-associated Human immunodeficiency virus infection in adults and pediatric populations when used with nucleoside reverse transcriptase inhibitors recommended by panels including the International Antiviral Society–USA and the British HIV Association. In clinical practice, lopinavir/ritonavir combinations were incorporated into first-line and second-line regimens alongside agents such as zidovudine, lamivudine, tenofovir disoproxil, and emtricitabine in protocols influenced by trials run by groups like the ACTG. Lopinavir has also been deployed in programmatic responses coordinated by agencies such as the Centers for Disease Control and Prevention and UNAIDS in resource-limited settings supported by procurement frameworks used by UNICEF.

Pharmacology

Lopinavir is a protease inhibitor targeting the HIV-1 protease enzyme first characterized structurally by investigators working in structural biology at institutions like Harvard University and Massachusetts Institute of Technology. Co-administration with ritonavir produces pharmacokinetic boosting via inhibition of cytochrome P450 3A4, a principle described in pharmacology texts used at universities such as Johns Hopkins University and University College London. Pharmacokinetic parameters were delineated in clinical pharmacology studies often cited by regulatory authorities including the Food and Drug Administration and the European Medicines Agency. Mechanistically, inhibition of HIV-1 protease leads to production of immature, noninfectious viral particles, a concept elaborated in reviews from laboratories at Cold Spring Harbor Laboratory and the Max Planck Institute.

Adverse effects

Common adverse effects of lopinavir/ritonavir combinations were identified in randomized controlled trials sponsored by companies like AbbVie and academic groups such as the INSIGHT network, and reported to regulators including the Food and Drug Administration. Frequently observed issues include gastrointestinal disturbances noted in cohorts studied at institutions like University College Hospital and metabolic effects described in follow-up studies at the Mayo Clinic and Cleveland Clinic. Hepatic enzyme elevations have been monitored by hepatology services at centers such as King's College Hospital and the Royal Free Hospital. Rare but serious events have been adjudicated by data safety monitoring boards similar to those convened for trials led by the National Institutes of Health.

Drug interactions

Lopinavir’s interaction profile arises principally from cytochrome P450 3A4 inhibition and was cataloged in interaction compendia used by pharmacists at Johns Hopkins Hospital and Guy's and St Thomas' NHS Foundation Trust. Significant interactions have been reported with drugs managed by specialists at the American Heart Association and European Society of Cardiology—for example, with antiarrhythmics and statins evaluated in pharmacology reviews at the American College of Cardiology. Interactions relevant to tuberculosis treatment were addressed in programs run by the World Health Organization and Stop TB Partnership, reflecting coadministration concerns with rifampicin-containing regimens. Guidance documents from the British HIV Association and the International Antiviral Society–USA summarize contraindications and dose adjustments.

Chemistry and formulation

The molecular design of lopinavir was reported in medicinal chemistry papers from teams at Bristol-Myers Squibb and described in texts used at California Institute of Technology and University of Cambridge. Formulations include coformulated tablets combining lopinavir with ritonavir; manufacturing and bioavailability issues have been handled by pharmaceutical units such as those at Pfizer and AbbVie production sites. Stability and excipient selection align with regulatory standards enforced by agencies like the European Medicines Agency and the Food and Drug Administration, and are considered in pharmacopeial monographs used by the United States Pharmacopeia.

History and society

Lopinavir was developed in the context of the late 1990s antiretroviral expansion and commercialized in formulations that played a role in global treatment scale-up initiatives supported by UNAIDS, the Global Fund, and bilateral programs like PEPFAR. Intellectual property and access issues involving manufacturers and advocacy groups such as Médecins Sans Frontières and Oxfam influenced licensing arrangements and generic production in countries represented by organizations like the World Trade Organization. National treatment policies in countries such as South Africa, Brazil, and India incorporated lopinavir-containing regimens in national formularies and procurement strategies managed through agencies like Health Canada and the Ministry of Health and Family Welfare (India).

Research and development

Clinical trials assessing lopinavir combinations were coordinated by consortia including the ACTG and international collaborative groups like the INSIGHT network, with outcomes informing guidelines from the World Health Organization and the European AIDS Clinical Society. Post-marketing research explored formulation improvements, pediatric dosing studied at pediatric centers like Great Ormond Street Hospital and St. Jude Children's Research Hospital, and resistance patterns characterized by laboratories collaborating with the Los Alamos National Laboratory HIV sequence database. Investigations into repurposing or adjunctive use were discussed in conferences such as the Conference on Retroviruses and Opportunistic Infections and the International AIDS Conference.

Category:Antiretroviral drugs